FDA Approves Lurbinectedin + Atezolizumab for ES-SCLC: IMforte Trial Breakdown

ARTICLE: https://oncologytube.com/fda-approves...
Discover the latest FDA approval of lurbinectedin combined with atezolizumab for extensive-stage small cell lung cancer (ES-SCLC) maintenance therapy. This video dives into the IMforte trial results, showcasing median overall survival (13.2 vs 10.6 months, HR 0.73), progression-free survival (5.4 vs 2.1 months, HR 0.54), response rates, and safety data (Grade 3/4 AEs 38% vs 22%). Perfect for oncology professionals. Visit OncologyTube.com for more insights and resources. Subscribe for updates!

Timestamps

00:00 - OncologyTube Exclusive Video!
00:02 - FDA Approves Lurbinectedin with Atezolizumab for ES-SCLC
00:06 - IMforte Trial: 660 Patients Enrolled, 483 Randomized
00:17 - Median Overall Survival: 13.2 vs 10.6 Months
00:33 - Median Progression-Free Survival: 5.4 vs 2.1 Months
00:59 - Safety Data: Grade 3/4 AEs and Serious AEs
01:13 - Related Video and Call to Action

About OncologyTube.com:
OncologyTube.com is a free video-sharing platform dedicated to oncology professionals, offering cancer research updates through videos, audio, PowerPoint presentations, and more. Visit OncologyTube.com for a detailed web post on this and many other cancer topics and oncology insights.

Follow OncologyTube:
eNewsletter: https://oncologytube.com/newsletter/
Twitter:   / oncologytube  
LinkedIn:   / oncologytube-com  
Facebook:   / oncologytube  
Instagram:   / oncologytube  
YouTube:    / oncologytube  

Connect with Us:
Share your thoughts in the comments! Join the discussion.